Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support

被引：4
|
作者：
Pennese, Elsa [1 ]
Vergine, Carolina [1 ]
Matera, Rosella [1 ]
Dargenio, Michela [1 ]
Forese, Pasquale [1 ]
Di Renzo, Nicola [1 ]
机构：
[1] Vito Fazzi Hosp, Hematol & Stem Cell Transplantat Unit, I-73100 Lecce, Italy
来源：
LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 11期
关键词：
PRIMARY CNS LYMPHOMAS; SALVAGE THERAPY; TEMOZOLOMIDE; CYTARABINE; ETOPOSIDE; TRIAL;
D O I：
10.3109/10428194.2011.585672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2188 / 2189
页数：2
相关论文
共 48 条
  • [21] High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom
    Kassam, S.
    Chernucha, E.
    O'Neill, A.
    Hemmaway, C.
    Cummins, T.
    Montoto, S.
    Lennard, A.
    Adams, G.
    Linton, K.
    McKay, P.
    Davies, D.
    Rowntree, C.
    Easdale, S.
    Eyre, T. A.
    Marcus, R.
    Cwynarski, K.
    Fox, C. P.
    BONE MARROW TRANSPLANTATION, 2017, 52 (09) : 1268 - 1272
  • [22] BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: A single center comparative analysis of efficacy and toxicity
    Kim, Jeong Eun
    Lee, Dae Ho
    Yoo, Changhoon
    Kim, Shin
    Kim, Sang-We
    Lee, Jung-Shin
    Park, Chan Jeong
    Huh, Jooryung
    Suh, Cheolwon
    LEUKEMIA RESEARCH, 2011, 35 (02) : 183 - 187
  • [23] R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
    Lee, Ji Yun
    Paik, Jin Ho
    Suh, Koung Jin
    Kim, Ji-Won
    Kim, Se Hyun
    Kim, Jin Won
    Kim, Yu Jung
    Lee, Keun-Wook
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong-Seok
    Lee, Jeong-Ok
    BLOOD RESEARCH, 2021, 56 (04) : 285 - 292
  • [24] Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
    Duarte, Bruno K. L.
    Valente, Isabella
    Vigorito, Afonso C.
    Aranha, Francisco J. P.
    Oliveira-Duarte, Gislaine
    Miranda, Eliana C. M.
    Lorand-Metze, Irene
    Pagnano, Katia B.
    Delamain, Marcia
    Marques Junior, Jose F.
    Brandalise, Silvia R.
    Nucci, Marcio
    De Souza, Carmino A.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (06): : 449 - 454
  • [25] Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
    Vose, Julie M.
    Habermann, Thomas M.
    Czuczman, Myron S.
    Zinzani, Pier Luigi
    Reeder, Craig B.
    Tuscano, Joseph M.
    Lossos, Izidore S.
    Li, Ju
    Pietronigro, Dennis
    Witzig, Thomas E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 639 - 647
  • [26] A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results
    Srour, Samer A.
    Li, Shaoying
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Lozano-Cerrada, Sara
    Maadani, Farzeneh
    Alousi, Amin
    Kebriaei, Partow
    Anderlini, Paolo
    Nieto, Yago
    Jones, Roy
    Shpall, Elizabeth
    Champlin, Richard E.
    Hosing, Chitra
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (04) : 561 - 570
  • [27] Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support
    Kollmannsberger, C
    Schleucher, N
    Rick, O
    Metzner, B
    Hartmann, JT
    Schöffski, P
    Beyer, J
    Casper, J
    Sosada, M
    Schmoll, HJ
    Böhlke, I
    Meisner, C
    Kanz, L
    Bokemeyer, C
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) : 775 - 782
  • [28] Immune reconstitution with high-dose chemotherapy and autologous stem cell transplantation in refractory and relapsed Hodgkin lymphoma: Prognostic factors and outcome from a single-center experience
    Yousif, Fawaz S.
    Matti, Bassam Francis
    Sabir, Shahla'a Fadhil
    AL-Bakri, Zena A.
    Faraj, Safa A.
    Mohammed, Mazin A.
    Shakir, Zahraa S.
    Khalid, Mahmood W.
    Hlali, Saba H. Al
    Saeb, Sarah M.
    TRANSPLANT IMMUNOLOGY, 2025, 89
  • [29] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma
    Sun Jin Sym
    Dae Ho Lee
    Hye Jin Kang
    Seung Hyun Nam
    Ho Young Kim
    Seok Jin Kim
    Hyeon Seok Eom
    Won Seog Kim
    Cheolwon Suh
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 27 - 33
  • [30] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
    Sym, Sun Jin
    Lee, Dae Ho
    Kang, Hye Jin
    Nam, Seung Hyun
    Kim, Ho Young
    Kim, Seok Jin
    Eom, Hyeon Seok
    Kim, Won Seog
    Suh, Cheolwon
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
12345